Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry

Sayama, Yusuke; Sano, M.; Kaneko, Mika K.; Kato, Yukinari

doi:10.1089/mab.2019.0045

Cited by 11 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C39Mab-1 (an anti-mCD39 mAb) [37], LpMab-7 (an anti-RIEDL [R*] tag mAb) [38][39][40][41][42][43][44][45][46], and NZ-1 (an anti-PA tag mAb) [47][48][49][50][51][52][53] were described previously. An anti-mCD39 mAb (clone 5F2, mouse IgG1, kappa) was purchased from BioLegend (San Diego, CA).…”

Section: Antibodiesmentioning

confidence: 99%

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning

Okada,

Suzuki,

Tanaka

et al. 2024

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Self Cite

View full text Add to dashboard Cite

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular ATP into immunosuppressive adenosine with another ectonucleotidase CD73. The elevated adenosine in the tumor microenvironment (TME) attenuates antitumor immunity, which promotes tumor cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), which suppress the enzymatic activity, can be applied to antitumor therapy. Therefore, an understanding of the relationship between the inhibitory activity and epitope of mAbs is important. We previously established an anti-mouse CD39 (mCD39) mAb, C39Mab-1 using the Cell-Based Immunization and Screening (CBIS) method. In this study, we determined the critical epitope of C39Mab-1 using flow cytometry. We performed the PA tag (12 amino acids)-substituted analysis (named PA scanning) and RIEDL tag (5 amino acids)-substituted analysis (named RIEDL scanning) to determine the critical epitope of C39Mab-1 using flow cytometry. By the combination of PA scanning and RIEDL scanning, we identified the conformational epitope, spanning three segments of 275 th to 279 th , 282 nd to 291 st , and 306 th to 323 rd amino acids of mCD39. These analyses would contribute to the identification of the conformational epitope of membrane proteins.

show abstract

Section: Antibodiesmentioning

confidence: 99%

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning

Okada,

Suzuki,

Tanaka

et al. 2024

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…PLAG stands for "platelet aggregation-stimulating", which is derived from the platelet aggregation-inducing function of PDPN [3]. Furthermore, several PLAG-like domains (PLDs, one of which is also named the PLAG4 domain) with similar sequences have been identified [4][5][6][7][8][9][10][11][12]. About half of the molecular weight of PDPN comes from O-type sugar chains.…”

Section: Pdpn Structure and Functions 1pdpn Structurementioning

confidence: 99%

Roles of Podoplanin in Malignant Progression of Tumor

Suzuki

Kaneko

Kato

2022

Cells

Self Cite

View full text Add to dashboard Cite

Podoplanin (PDPN) is a cell-surface mucin-like glycoprotein that plays a critical role in tumor development and normal development of the lung, kidney, and lymphatic vascular systems. PDPN is overexpressed in several tumors and is involved in their malignancy. PDPN induces platelet aggregation through binding to platelet receptor C-type lectin-like receptor 2. Furthermore, PDPN modulates signal transductions that regulate cell proliferation, differentiation, migration, invasion, epithelial-to-mesenchymal transition, and stemness, all of which are crucial for the malignant progression of tumor. In the tumor microenvironment (TME), PDPN expression is upregulated in the tumor stroma, including cancer-associated fibroblasts (CAFs) and immune cells. CAFs play significant roles in the extracellular matrix remodeling and the development of immunosuppressive TME. Additionally, PDPN functions as a co-inhibitory molecule on T cells, indicating its involvement with immune evasion. In this review, we describe the mechanistic basis and diverse roles of PDPN in the malignant progression of tumors and discuss the possibility of the clinical application of PDPN-targeted cancer therapy, including cancer-specific monoclonal antibodies, and chimeric antigen receptor T technologies.

show abstract

“…PLAG stands for "platelet aggregation-stimulating," which is derived from the platelet aggregation-inducing function of PDPN [3]. Furthermore, several PLAG-like domains (PLDs, one of which is also named PLAG4 domain) with similar sequences were identified [4][5][6][7][8][9][10][11][12]. About half of the molecular weight of PDPN is O-type sugar chains.…”

Section: Pdpn Structurementioning

confidence: 99%

Roles of Podoplanin in Malignant Progression of Tumor

Suzuki¹,

Kaneko²,

Kato³

2022

Preprint

Self Cite

View full text Add to dashboard Cite

Podoplanin (PDPN) is a cell-surface mucin-like glycoprotein that plays a critical role in tumor development and normal development of the lung, kidney, and lymphatic vascular systems. PDPN is overexpressed in several tumors and is involved in their malignancy. PDPN induces platelet aggregation through binding to platelet receptor C-type lectin-like receptor 2. Furthermore, PDPN modulates signal transductions that regulate cell proliferation, differentiation, migration, invasion, epithelial to mesenchymal transition, and stemness, all of which are crucial for the malignant progression of tumor. In the tumor microenvironment (TME), PDPN expression is up-regulated in the tumor stroma, including cancer-associated fibroblasts (CAFs) and immune cells. CAFs play significant roles in the extracellular matrix remodeling and the development of immunosuppressive TME. Additionally, PDPN functions as a co-inhibitory molecule on T cells, indicating the involvement with immune evasion. In this review, we describe the mechanistic basis and diverse roles of PDPN in malignant progression of tumor and discuss the possibility of the clinical application of PDPN-targeted cancer therapy, including cancer-specific monoclonal antibodies, and chimeric antigen receptor T technologies.

show abstract

Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry

Cited by 11 publications

References 51 publications

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning

Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning

Roles of Podoplanin in Malignant Progression of Tumor

Roles of Podoplanin in Malignant Progression of Tumor

Contact Info

Product

Resources

About